Pregled bibliografske jedinice broj: 172005
Thyroid stunning in vivo and in vitro
Thyroid stunning in vivo and in vitro // Nuclear medicine communications, 26 (2005), 8; 731-735 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 172005 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Thyroid stunning in vivo and in vitro
Autori
Medvedec, Mario
Izvornik
Nuclear medicine communications (0143-3636) 26
(2005), 8;
731-735
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
dosimetry; radioiodine therapy; thyroid cancer; thyroid disease; thyroid stunning
Sažetak
Aim was to review published in-vivo and in-vitro quantitative dosimetric studies on thyroid stunning in order to derive novel data applicable in clinical practice. A non-linear regression analysis was applied to describe the extent of thyroid stunning in thyroid remnants, as a function of the radiation absorbed dose of diagnostic radioiodine-131 (I-131), in thyroid cancer patients investigated in four in-vivo studies. The regression curves were fitted using individual patient absorbed doses or the mean absorbed doses for the groups of patients. Fitted curves were compared with two recent models, the first found in patients with benign thyroid disease and the second found in cultured thyroid cells after I-131 irradiation. The extrapolated absorbed doses for the onset of thyroid stunning were 0 Gy delivered to thyroid cells in vitro, and <=4Gy and 34 Gy delivered to thyroid cells in vivo (malignant and benign conditions, respectively). Thyroid stunning amounted to roughly 50% in the case of 2 Gy delivered to thyroid cells in vitro, and in the case of <=30Gy and 472 Gy delivered to thyroid cells in vivo (malignant and benign conditions, respectively). There is no scintigraphically sufficient diagnostic amount of I-131 that can be given prior to I-131 therapy for thyroid cancer that does not cause thyroid stunning, i.e. it is not recommended to deliver pre-therapeutically more than a few gray (<5 Gy) into thyroid remnants. More investigations are required to confirm the proposed in-vitro and benign in-vivo models, but characteristic absorbed doses presented so far for in-vitro vs. in-vivo malignant vs. in-vivo benign thyroid environments differ roughly by an order of magnitude.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- CA Search (Chemical Abstracts)
- EMBASE (Excerpta Medica)
- MEDLINE
- Scisearch
- Research Alert
- Medical Documentation Service
- Biomedical Engineering Citation Index
- Current Awareness in Biological Sciences